胸骨旁阻滞减少冠脉搭桥术劈胸骨期阿片类药物用量:随机对照试验
本研究为双盲随机安慰剂对照试验,纳入35例择期冠脉搭桥手术患者,术前分别接受罗哌卡因或生理盐水胸骨旁平面阻滞。结果显示胸骨旁阻滞组劈胸骨期维持血流动力学稳定的瑞芬太尼和丙泊酚最大浓度显著降低,且术后炎症因子水平下降。
要点
- 术前胸骨旁阻滞可降低劈胸骨期瑞芬太尼最大效应室浓度。
- 胸骨旁阻滞组丙泊酚用量更低且镇静深度更适宜。
- 胸骨旁阻滞减轻术后7天内炎症因子水平。
核心结论
- 术前胸骨旁平面阻滞可减少冠脉搭桥术劈胸骨期维持血流动力学稳定和麻醉深度所需的瑞芬太尼和丙泊酚最大浓度。
研究设计与样本
- 双盲、随机、安慰剂对照试验,前瞻性纳入35例择期全麻下冠脉搭桥手术患者。
- 患者按1:1随机接受术前罗哌卡因或生理盐水胸骨旁平面阻滞。
- 主要终点为劈胸骨期维持心率和血压在推荐范围内所需的瑞芬太尼最大效应室浓度。
主要发现
- 胸骨旁阻滞组劈胸骨期瑞芬太尼最大浓度中位数为4.2(2.5-6.0)ng/mL,安慰剂组为7.0(5.2-8.0)ng/mL(p=0.02)。
- 胸骨旁阻滞组丙泊酚最大浓度均值为3.9±1.1 µg/mL,安慰剂组为5.0±1.5 µg/mL(p=0.02)。
- 最低患者状态指数在安慰剂组为11.7±8.7,胸骨旁阻滞组为18.3±6.8(p=0.02)。
- 胸骨旁阻滞组术后7天内促炎细胞因子IL-8、IL-18、IL-23、IL-33和MCP-1浓度降低(p<0.05)。
临床怎么用
- 冠脉搭桥术前可考虑实施胸骨旁平面阻滞,以减少劈胸骨期阿片类和丙泊酚用量并减轻炎症反应。
局限性
- 样本量较小(35例),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to assess the effect of a preoperative parasternal plane block (PSB) on opioid consumption required to maintain hemodynamic stability during sternotomy for coronary artery bypass graft surgery. METHODS: This double-blind, randomized, placebo-controlled trial prospectively enrolled 35 patients scheduled for coronary artery bypass graft surgery under general anesthesia with propofol and remifentanil. Patients were randomized to receive preoperative PSB using either ropivacaine (PSB group) or saline solution (placebo group) (1:1 ratio). The primary endpoint was the maximal effect-site concentration of remifentanil required to maintain heart rate and blood pressure within the recommended ranges during sternotomy. RESULTS: Median maximum concentration of remifentanil necessary to maintain adequate hemodynamic status during sternotomy was significantly reduced in PSB group (4.2 (2.5-6.0) ng/mL) compared with placebo group (7.0 (5.2-8.0) ng/mL) (p=0.02). Mean maximum concentration of propofol used to control depth of anesthesia was also reduced (3.9±1.1 µg/mL vs 5.0±1.5 µg/mL, PSB vs placebo, respectively; p=0.02). This reduction in propofol consumption during sternotomy enabled a more adequate level of sedation to be maintained in patients (minimum patient state index was 11.7±8.7 in placebo group and 18.3±6.8 in PSB group; p=0.02). PSB reduced postoperative inflammatory response by limiting concentrations of proinflammatory cytokines IL-8, IL-18, IL-23, IL-33 and MCP-1 measured in the first 7-day after surgery (p<0.05). CONCLUSIONS: Preoperative PSB reduced the maximum concentrations of remifentanil and propofol required to maintain hemodynamic stability and depth of anesthesia during sternotomy. TRIAL REGISTRATION NUMBER: NCT03734159.Sébastien Bloc, M.D.1,2; Brieuc P. Pérot, Ph.D.3; Hadrien Gibert, M.D.1; Jean-Dominique Law Koune, M.D.1; Yannick Burg, M.D.1; Didier Leclerc, M.D.1; Anne-Sophie Vuitton, M.D.1; Christophe De La Jonquière, M.D.1; Marine Luka, L.S.3; Thierry Waldmann, M.D.4; Nicolas Vistarini, M.D.4; Stéphane Aubert, M.D.4; Mickaël M. Ménager, Ph.D.3; Messaouda Merzoug, Ph.D.2; Cécile Naudin, Ph.D.2; Pierre Squara, M.D.2,5.
引用
- Bloc S, Perot BP, Gibert H, et al. Efficacy of parasternal block to decrease intraoperative opioid use in coronary artery bypass surgery via sternotomy: a randomized controlled trial. Reg Anesth Pain Med. 2021. PMID: 33990437. doi:10.1136/rapm-2020-102207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。